ADVERTISEMENT

Glofitamab shows promise against relapsed or refractory diffuse large B-cell lymphoma

Pavankumar Kamat   |   Clinical Summary   |   27 June 2022
ADVERTISEMENT

Takeaway

  • Nearly half of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) demonstrated a clinical response to glofitamab.

Why this matters

  • Bispecific T-cell-recruiting antibodies are emerging therapeutic options for B-cell cancers.

Study design

  • The phase 2 study included 154 adults with DLBCL (median age, 66 years; 65% male)...

          

Topic Challenges

left
right